Furthermore, it is unclear whether a routine use of plasma renin activity assays whilst selecting the first line antihypertensive agents would add significantly to the BP control achieved compared with that achieved using simpler phenotypical correlates, such as race, age and possibly presence of obesity. The gene discussed is REN; the disease is obesity due to melanocortin 4 receptor deficiency.